🔗 Share this article

An everyday slimming pill may help individuals cut their body weight by up to 20%, according to a study that might pave the way for millions more people to lose weight.

How the Drug Functions

The drug, called the oral treatment, targets the same GLP-1 pathways as weight loss shots such as tirzepatide and Wegovy. During research of 3,127 participants, one in five people who used the daily pill for 72 weeks lost 20% or more of their body weight.

Weight loss jabs have been revolutionary, but oral forms are seen as a major breakthrough since they are easier to store, share and administer, and may also be projected to be cheaper, offering new optimism for millions attempting to lose weight.

Orforglipron is a GLP-1 stimulant, a class of drug that aids in lowering blood sugar readings, slows the digestion of meals and may reduce hunger.

Trial Findings and Convenience

Slimming results observed among participants using the tablet are less stark as that in users using tirzepatide, but experts think the oral form will be easier to obtain and convenient compared with injections.

The drug has not been authorized by the US Food and Drug Administration or health authorities in additional nations. Developers stated it expects significant interest once the oral treatment is launched.

In the study, the over three thousand patients were divided into cohorts receiving orforglipron tablets of different dosages, while others received a dummy pill, for 72 weeks.

All of the patients were diagnosed with obesity, indicating they had a BMI reading of 30 or over, but they did not have high blood sugar. Participants from several countries were involved in the study.

Key Results

Researchers found that following the study period users on the lowest dose reduced an mean of 7.5% of their weight. Participants on the highest dose lost an average of 11.2% of their body weight.

In patients taking the highest doses, more than half had a decrease of at least 10% of body weight, over a third had a loss of 15% or greater, and almost one-fifth had a reduction of 20% or higher.

The team said other wellness indicators also got better among people taking the drug, including better BP, a reduced waist circumference and a decrease in LDL levels.

Frequent adverse reactions were gastrointestinal, which were said to be manageable.

“Among participants with obesity, 72-week use using the medication led to significantly greater decreases in weight than inactive treatment,” the authors wrote.

Potential Impact

Health leaders have hailed weight loss drugs as transformative. But shots come with extra work for medical systems, so oral options might help millions more people aiming to lose weight.

Additional research shows weight loss injections could be effective on minors starting from age six who have obesity or are diagnosed with type 2 diabetes. However, digestive issues were “significantly more common” among young users using the drugs.

Experts emphasized that extended follow-up durations in upcoming studies and more real-world research were “essential to establish the long-term effects.”